We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.
Our common stock is listed on the Nasdaq Capital Market under the symbol MATN.
We are headquartered in South San Francisco, California.
Events & Presentations
Sep 27, 2016 at 4:00 PM ET
Ladenburg Thalmann 2nd Annual Healthcare Conference
Sep 12, 2016 at 12:30 PM ET
Rodman & Renshaw 18th Annual Global Investment Conference
Jun 27, 2016 at 12:00 PM ET
Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer